Synergistically Enhanced in-Vitro Cytotoxicity and Overall Survival in NSG Xenografts Against Burkitt Lymphoma (BL) and Primary Mediastinal Large B Cell Lymphoma (PMBL) by Polatuzumab Vedotin (hu- anti-CD79b-vc-MMAE, PV) Alone or In-Combination With Obinutuzumab
Document Type
Abstract
Publication Date
9-2018
DOI
10.1111/bjh.15536
Journal Title
British Journal of Haematology
Department
Pediatrics
Second Department
Health Behavior and Community Health
Recommended Citation
Awasthi, A., Edani, D., Ayello, J., Klein, C., & Cairo, M. S. (2018). Synergistically Enhanced in-Vitro Cytotoxicity and Overall Survival in NSG Xenografts Against Burkitt Lymphoma (BL) and Primary Mediastinal Large B Cell Lymphoma (PMBL) by Polatuzumab Vedotin (hu- anti-CD79b-vc-MMAE, PV) Alone or In-Combination With Obinutuzumab. British Journal of Haematology, 182 (Suppl. 1), 47-48. https://doi.org/10.1111/bjh.15536
COinS